Valuation: SCYNEXIS, Inc.

Market Cap 4.02Cr 3.52Cr 3.27Cr 3.01Cr 5.66Cr 388.08Cr 5.75Cr 39Cr 15Cr 189.89Cr 15Cr 15Cr 655.99Cr P/E 2026 *
-0.99x
P/E 2027 * -1.61x
Enterprise Value 4.02Cr 3.52Cr 3.27Cr 3.01Cr 5.66Cr 388.08Cr 5.75Cr 39Cr 15Cr 189.89Cr 15Cr 15Cr 655.99Cr EV / Sales 2026 *
34.9x
EV / Sales 2027 * 6.02x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+0.62%
1 week-15.63%
Current month+0.12%
1 month+7.24%
3 months-50.55%
6 months-32.61%
Current year-19.45%
1 week 3.87
Extreme 3.87
4.82
1 month 3.68
Extreme 3.68
5.1
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
64.8
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Free

Director

5,750 0.0579%
26/06/26 Free

Director

5,750 0.0579%
26/06/26 Free

Director

5,750 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-15.63%-28.26%-81.13% 4.02Cr
-1.00%+0.51%+49.73%+153.10% 1,04800Cr
+1.58%+3.02%+51.54%+48.75% 60TCr
-0.94%+4.00%+35.68%+77.30% 45TCr
-0.42%+0.67%+30.81%+21.54% 33TCr
-0.16%+2.74%+36.02%+38.04% 28TCr
+1.68%+1.08%+22.70%+17.83% 26TCr
-1.40%-3.34%-24.63%-41.91% 22TCr
+0.40%+2.54%+20.19%+56.06% 20TCr
+0.95%-0.04%+19.50%+69.52% 16TCr
Average +0.15%-0.22%+21.33%+35.91% 35.52TCr
Weighted average by Cap. -0.08%+1.69%+35.84%+73.33%

Financials

2026 *2027 *
Net sales 11.54L 10.11L 9L 9L 16.25L 11Cr 16.49L 1.12Cr 43.77L 5.45Cr 43.32L 42.39L 19Cr 66.77L 58.51L 54.31L 49.91L 94.05L 64Cr 95.43L 6.47Cr 2.53Cr 32Cr 2.51Cr 2.45Cr 108.91Cr
Net income -4.11Cr -3.6Cr -3.34Cr -3.07Cr -5.79Cr -396.34Cr -5.87Cr -40Cr -16Cr -193.93Cr -15Cr -15Cr -669.95Cr -2.87Cr -2.52Cr -2.34Cr -2.15Cr -4.05Cr -277.23Cr -4.11Cr -28Cr -11Cr -135.65Cr -11Cr -11Cr -468.6Cr
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
22/26/22 $4.075 +0.62% 13,026
21/26/21 $4.050 +3.98% 38,236
20/26/20 $3.895 -8.78% 51,889
17/26/17 $4.270 -4.69% 22,838
16/26/16 $4.480 -7.25% 33,685
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.050USD
Average target price
33.55USD
Spread / Average Target
+728.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock